Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
- PMID: 25896535
- DOI: 10.1038/tpj.2015.29
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
Abstract
Genetic biomarkers could be useful for orienting treatment of patients with rheumatoid arthritis (RA), but none has been convincingly validated yet. Putative biomarkers include 14 single nucleotide polymorphisms that have shown association with response to TNF inhibitors (TNFi) in candidate gene studies and that we assayed here in 755 RA patients. Three of them, in the PTPRC, IL10 and CHUK genes, were significantly associated with response to TNFi. The most significant result was obtained with rs10919563 in PTPRC, which is a confirmed RA susceptibility locus. Its RA risk allele was associated with improved response (B=0.33, P=0.006). This is the second independent replication of this biomarker (P=9.08 × 10(-8) in the combined 3003 RA patients). In this way, PTPRC has become the most replicated genetic biomarker of response to TNFi. In addition, the positive but weaker replication of IL10 and CHUK should stimulate further validation studies.
Similar articles
-
Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.Rheumatol Int. 2016 Jun;36(6):837-44. doi: 10.1007/s00296-016-3476-5. Epub 2016 Apr 13. Rheumatol Int. 2016. PMID: 27074847 Review.
-
Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort.Arthritis Rheum. 2012 Mar;64(3):665-70. doi: 10.1002/art.33381. Arthritis Rheum. 2012. PMID: 21952740 Free PMC article.
-
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.Arthritis Rheum. 2010 Jul;62(7):1849-61. doi: 10.1002/art.27457. Arthritis Rheum. 2010. PMID: 20309874 Free PMC article.
-
TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy.Biomed Res Int. 2015;2015:490295. doi: 10.1155/2015/490295. Epub 2015 Mar 5. Biomed Res Int. 2015. PMID: 25834819 Free PMC article.
-
Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.Dan Med J. 2016 Nov;63(11):B5311. Dan Med J. 2016. PMID: 27808043 Review.
Cited by
-
Towards Personalized Medicine in Rheumatoid Arthritis.Open Access Rheumatol. 2024 May 18;16:89-114. doi: 10.2147/OARRR.S372610. eCollection 2024. Open Access Rheumatol. 2024. PMID: 38779469 Free PMC article. Review.
-
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?Arthritis Res Ther. 2017 Oct 24;19(1):239. doi: 10.1186/s13075-017-1445-3. Arthritis Res Ther. 2017. PMID: 29065909 Free PMC article. Review.
-
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis.Pharmacogenomics J. 2018 Sep;18(5):657-664. doi: 10.1038/s41397-018-0040-6. Epub 2018 Aug 31. Pharmacogenomics J. 2018. PMID: 30166627 Free PMC article.
-
Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis.Biomedicines. 2022 Jul 27;10(8):1808. doi: 10.3390/biomedicines10081808. Biomedicines. 2022. PMID: 36009355 Free PMC article.
-
Promising targets and drugs in rheumatoid arthritis: a module-based and cumulatively scoring approach.Bone Joint Res. 2020 Aug 2;9(8):501-514. doi: 10.1302/2046-3758.98.BJR-2019-0301.R1. eCollection 2020 Aug. Bone Joint Res. 2020. PMID: 32922758 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous